Development of hepatocellular carcinoma after hepatitis C virus eradication in interferon-free direct-acting antivirals

Development of hepatocellular carcinoma after hepatitis C virus eradication in interferon-free direct-acting antivirals - Development of hepatocellular carcinoma after direct-acting antivirals

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027342

Enrollment

2000

Registered

2017-05-15

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) chronic hepatitis C patients

Exclusion criteria

Exclusion criteria: (1) under age 20 at the initiation of treatment (2) decompensated cirrhosis with Child-Pugh B or C (3) concomitant human immunodeficiency virus or hepatitis B virus infection (4) excessive active alcohol consumption

Design outcomes

Primary

Measure	Time frame
Rates of the HCC development after DAA treatment.	—

Secondary

Measure	Time frame
Factors associated with HCC development.	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

Kyushu University Hospital Department of General Internal Medicine

e.ogawa.a65@m.kyushu-u.ac.jp092-642-5909

Outcome results